These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 35244787)

  • 1. Effects of oligomer toxicity, fibril toxicity and fibril spreading in synucleinopathies.
    Cascella R; Bigi A; Cremades N; Cecchi C
    Cell Mol Life Sci; 2022 Mar; 79(3):174. PubMed ID: 35244787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies.
    Bigi A; Cascella R; Cecchi C
    Neural Regen Res; 2023 Nov; 18(11):2332-2342. PubMed ID: 37282450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stabilization of α-Synuclein Fibril Clusters Prevents Fragmentation and Reduces Seeding Activity and Toxicity.
    Lam HT; Graber MC; Gentry KA; Bieschke J
    Biochemistry; 2016 Feb; 55(4):675-85. PubMed ID: 26799377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining α-synuclein species responsible for Parkinson's disease phenotypes in mice.
    Froula JM; Castellana-Cruz M; Anabtawi NM; Camino JD; Chen SW; Thrasher DR; Freire J; Yazdi AA; Fleming S; Dobson CM; Kumita JR; Cremades N; Volpicelli-Daley LA
    J Biol Chem; 2019 Jul; 294(27):10392-10406. PubMed ID: 31142553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports.
    Lashuel HA
    Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities.
    Alam P; Bousset L; Melki R; Otzen DE
    J Neurochem; 2019 Sep; 150(5):522-534. PubMed ID: 31254394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiological C-terminal truncation of α-synuclein potentiates the prion-like formation of pathological inclusions.
    Sorrentino ZA; Vijayaraghavan N; Gorion KM; Riffe CJ; Strang KH; Caldwell J; Giasson BI
    J Biol Chem; 2018 Dec; 293(49):18914-18932. PubMed ID: 30327435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Pairs of Toxic and Nontoxic Misfolded Protein Oligomers Elucidates the Structural Determinants of Oligomer Toxicity in Protein Misfolding Diseases.
    Limbocker R; Cremades N; Cascella R; Tessier PM; Vendruscolo M; Chiti F
    Acc Chem Res; 2023 Jun; 56(12):1395-1405. PubMed ID: 37071750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role of α-synuclein truncation in aggregation and disease.
    Sorrentino ZA; Giasson BI
    J Biol Chem; 2020 Jul; 295(30):10224-10244. PubMed ID: 32424039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies.
    Villar-Piqué A; Lopes da Fonseca T; Outeiro TF
    J Neurochem; 2016 Oct; 139 Suppl 1():240-255. PubMed ID: 26190401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular models of alpha-synuclein toxicity and aggregation.
    Delenclos M; Burgess JD; Lamprokostopoulou A; Outeiro TF; Vekrellis K; McLean PJ
    J Neurochem; 2019 Sep; 150(5):566-576. PubMed ID: 31265132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein misfolding and aggregation: Implications in Parkinson's disease pathogenesis.
    Mehra S; Sahay S; Maji SK
    Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):890-908. PubMed ID: 30853581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Synuclein Fibrils Exhibit Gain of Toxic Function, Promoting Tau Aggregation and Inhibiting Microtubule Assembly.
    Oikawa T; Nonaka T; Terada M; Tamaoka A; Hisanaga S; Hasegawa M
    J Biol Chem; 2016 Jul; 291(29):15046-56. PubMed ID: 27226637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons.
    Colla E; Panattoni G; Ricci A; Rizzi C; Rota L; Carucci N; Valvano V; Gobbo F; Capsoni S; Lee MK; Cattaneo A
    Neurobiol Dis; 2018 Mar; 111():36-47. PubMed ID: 29246724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heme Stabilization of α-Synuclein Oligomers during Amyloid Fibril Formation.
    Hayden EY; Kaur P; Williams TL; Matsui H; Yeh SR; Rousseau DL
    Biochemistry; 2015 Aug; 54(30):4599-610. PubMed ID: 26161848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.